Plain-English translation of NCT05000294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two cancer medications: (an immunotherapy drug) and (a drug that targets blood vessel growth). Researchers believe that by combining these two drugs, they may be able to help people with certain difficult-to-treat cancers — including pancreatic cancer, prostate cancer, bile duct cancer, ovarian cancer, and others — respond better to treatment than they would with either drug alone.
Many people with certain types of cancer don't respond well to immunotherapy on its own. This medication combination is designed to work together: the blood vessel-targeting drug may help "wake up" the immune system so the immunotherapy can work better, even against tumors that have traditionally been resistant to this kind of treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the two study medications — likely as injections or infusions — on a regular schedule determined by the research team. You'll have frequent clinic visits for blood tests, imaging scans, and check-ups to monitor how you're responding and watch for side effects. The study involves two phases: Phase 1B focuses on safety in a small group, and Phase 2 looks at whether the combination actually helps people with specific cancer types.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States